MOUNTAIN VIEW, Calif., Jan. 27 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software and strategic services for optimizing clinical drug development, today announced three new staff additions in product training and Strategic Consulting Services.
“The addition of three new scientists increases our capacity to serve the needs of our clients,” said Shawn O’Connor, Pharsight president and chief executive officer. “Dr. Bachman’s expertise in modeling software, especially nonlinear mixed effects modeling, will improve Pharsight’s capability to train clients on both our current software offerings and anticipated launches. Drs. Krause and Warner will add to our drug-disease modeling and simulation capability in Europe and the US. They bring a combination of technical expertise and knowledge of drug development decision-making that we expect will be of significant value to our clients.”
William Bachman, Ph.D., joins as Senior Scientific Consultant in Pharsight’s Product Training organization. Dr. Bachman comes to Pharsight from the GloboMax division of ICON, where he was software project manager and head programmer for several products related to nonlinear mixed effects modeling, which is used for both regulatory and strategic population pharmacokinetics. Before Globomax, Dr. Bachman was with the U.S. Food and Drug Administration. Dr. Bachman received his Ph.D. in Pharmacy (Analytical Medicinal Chemistry) from the University of Georgia. He also completed a Postdoctoral Fellowship at the University of California, San Francisco. Dr. Bachman has more than 20 publications and presentations to his credit.
Andreas Krause, Ph.D., joins as Senior Scientist reporting to Dr. Rene Bruno, who heads Strategic Consulting Services in Europe. Dr. Krause comes to Pharsight after six years with Novartis AG in Basel, Switzerland. Before joining Novartis, Dr. Krause held positions at GeneData ('97-'00), Ciba-Geigy ('95-'97), and The Institute for Statistics and Econometrics at the University of Basel ('90-'94). He received his Ph.D. in Statistics from the University of Basel ('94). His thesis is titled “Gibbs Sampling in Regression Models.” He is a board member and book review editor for “Computational Statistics” and has authored several pivotal works on S-PLUS programming. Dr. Krause brings a focus on Bayesian techniques, Gibbs sampling, censored regression modeling, graphics and visualization, and nonparametric regression.
John Warner, Ph.D., joins as Senior Scientist in Strategic Consulting Services in the U.S. Dr. Warner comes to Pharsight from Novartis AG after four years as a Senior Biostatistician. Before joining Novartis, Dr. Warner worked with Bayer for three years as a Senior Statistician. Dr. Warner received his Ph.D. ('97) in statistics and M.A. ('79) and B.S. ('76) in Mathematics from the University of Michigan at Ann Arbor. His dissertation title is “Exact Optimal Designs for Estimating the Minimum of a Quadratic Response Surface via Stochastic Programming.” Dr. Warner’s focus includes clinical trial design (Phase I through IV), optimal design of experiments, Bayesian computations, nonlinear models, random effects modeling, data mining, and PK/PD analysis.
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company’s goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight’s approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com .
Forward Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding anticipated performance of Pharsight’s scientific consultants and the expected benefits to customers from the use of Pharsight’s services. Actual results may differ materially from Pharsight’s expectations due to a variety of factors, including general market and business conditions, uncertainties involved in pharmaceutical drug development, changes in the demand for Pharsight’s services, the failure to develop new services or to keep pace with technological changes, the failure of Pharsight’s services to obtain anticipated levels of customer acceptance or to meet customers’ expectations, and changes in government regulation of the pharmaceutical industry. Further information on potential factors that could affect actual results is included in Pharsight’s Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission on November 14, 2005. All forward-looking statements are based on information available to Pharsight as of the date hereof, and Pharsight assumes no obligation to update such statements, whether as a result of new developments or otherwise.
Registered Trademarks and Trademarks
Pharsight is a registered trademark of Pharsight Corporation.
Pharsight Corporation
CONTACT: investors, Douglas Sherk, +1-415-896-6820, or JenniferBeugelmans, 415-896-6820, or media, Steve DiMattia, +1-646-277-8706, all ofEVC Group, for Pharsight Corporation
Web site: http://www.pharsight.com/
